Literature DB >> 25282537

Botulinum neurotoxins: new questions arising from structural biology.

Richard A Kammerer1, Roger M Benoit2.   

Abstract

Botulinum neurotoxins (BoNTs) are the most toxic substances known and cause botulism in vertebrates. They have also emerged as effective and powerful reagents for cosmetic and medical applications. One important prerequisite for understanding BoNT function in disease, and the further development of the toxins for cosmetic and medical applications, is a detailed knowledge of BoNT interactions with non-toxic neurotoxin-associated proteins and cell surface receptors. Based on the substantial recent progress in obtaining high-resolution crystal structures of key BoNT complexes, we summarize the major advances in understanding BoNT interactions and discuss the resulting potential implications, in particular those relating to BoNT serotype A.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Botulinum neurotoxin; X-ray crystallography; cell surface receptors; progenitor-toxin complex; subtype

Mesh:

Substances:

Year:  2014        PMID: 25282537     DOI: 10.1016/j.tibs.2014.08.009

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  10 in total

1.  Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B.

Authors:  Alessandra Flores; Jorge Ramirez-Franco; Richard Desplantes; Kévin Debreux; Géraldine Ferracci; Florian Wernert; Marie-Pierre Blanchard; Yves Maulet; Fahamoe Youssouf; Marion Sangiardi; Cécile Iborra; Michel Robert Popoff; Michael Seagar; Jacques Fantini; Christian Lévêque; Oussama El Far
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-20       Impact factor: 11.205

Review 2.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Molecular landscape of BoNT/B bound to a membrane-inserted synaptotagmin/ganglioside complex.

Authors:  Jorge Ramirez-Franco; Fodil Azzaz; Marion Sangiardi; Géraldine Ferracci; Fahamoe Youssouf; Michel Robert Popoff; Michael Seagar; Christian Lévêque; Jacques Fantini; Oussama El Far
Journal:  Cell Mol Life Sci       Date:  2022-08-25       Impact factor: 9.207

Review 4.  On botulinum neurotoxin variability.

Authors:  Cesare Montecucco; Maria Berica Rasotto
Journal:  mBio       Date:  2015-01-06       Impact factor: 7.867

5.  Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C.

Authors:  Roger M Benoit; Martin A Schärer; Mara M Wieser; Xiaodan Li; Daniel Frey; Richard A Kammerer
Journal:  Sci Rep       Date:  2017-03-02       Impact factor: 4.379

Review 6.  Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity.

Authors:  Elena Fonfria; Mark Elliott; Matthew Beard; John A Chaddock; Johannes Krupp
Journal:  Toxins (Basel)       Date:  2018-07-04       Impact factor: 4.546

Review 7.  Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.

Authors:  Siro Luvisetto; Parisa Gazerani; Carlo Cianchetti; Flaminia Pavone
Journal:  Toxins (Basel)       Date:  2015-09-23       Impact factor: 4.546

8.  Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.

Authors:  Jasmin Weisemann; Daniel Stern; Stefan Mahrhold; Brigitte G Dorner; Andreas Rummel
Journal:  Toxins (Basel)       Date:  2016-05-17       Impact factor: 4.546

Review 9.  Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip.

Authors:  Domenico Azarnia Tehran; Marco Pirazzini
Journal:  Toxins (Basel)       Date:  2018-05-10       Impact factor: 4.546

Review 10.  Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics.

Authors:  Jonathan R Davies; Sai Man Liu; K Ravi Acharya
Journal:  Toxins (Basel)       Date:  2018-10-20       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.